DK0700284T3 - Oxybutyninformuleringer med kontrolleret frigivelse - Google Patents

Oxybutyninformuleringer med kontrolleret frigivelse

Info

Publication number
DK0700284T3
DK0700284T3 DK94913918T DK94913918T DK0700284T3 DK 0700284 T3 DK0700284 T3 DK 0700284T3 DK 94913918 T DK94913918 T DK 94913918T DK 94913918 T DK94913918 T DK 94913918T DK 0700284 T3 DK0700284 T3 DK 0700284T3
Authority
DK
Denmark
Prior art keywords
oxybutynine
formulations
controlled release
sustained release
solid oral
Prior art date
Application number
DK94913918T
Other languages
English (en)
Inventor
Anand Baichwal
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22766272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0700284(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Application granted granted Critical
Publication of DK0700284T3 publication Critical patent/DK0700284T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DK94913918T 1994-03-04 1994-03-18 Oxybutyninformuleringer med kontrolleret frigivelse DK0700284T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/206,416 US5399359A (en) 1994-03-04 1994-03-04 Controlled release oxybutynin formulations
PCT/US1994/002926 WO1995023593A1 (en) 1994-03-04 1994-03-18 Controlled release oxybutynin formulations

Publications (1)

Publication Number Publication Date
DK0700284T3 true DK0700284T3 (da) 2003-01-06

Family

ID=22766272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94913918T DK0700284T3 (da) 1994-03-04 1994-03-18 Oxybutyninformuleringer med kontrolleret frigivelse

Country Status (15)

Country Link
US (1) US5399359A (da)
EP (1) EP0700284B1 (da)
JP (2) JP3699117B2 (da)
CN (1) CN1111404C (da)
AT (1) ATE222753T1 (da)
AU (1) AU676556B2 (da)
CA (1) CA2161103C (da)
DE (1) DE69431247T2 (da)
DK (1) DK0700284T3 (da)
ES (1) ES2180574T3 (da)
FI (1) FI113337B (da)
HU (1) HUT72981A (da)
IL (1) IL112637A (da)
PT (1) PT700284E (da)
WO (1) WO1995023593A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
WO1996012477A1 (en) * 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
ES2141044B1 (es) * 1997-02-26 2001-02-01 Alza Corp Terapia con oxibutinina.
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2452871C (en) 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
AU2002356418A1 (en) * 2001-10-08 2003-04-22 Sun Pharmaceutical Industries Limited An antispasmodic agent spaced drug delivery system
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US20070092566A1 (en) * 2003-08-04 2007-04-26 Ryouichi Hoshino Oral sustained-release tablet
AP2006003585A0 (en) * 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS
EP1680110B1 (en) * 2003-11-04 2011-01-05 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
SI1877219T1 (sl) 2005-03-15 2012-02-29 Htc Sweden Ab Postopek za vzdrĺ˝evanje trdne gladke talne povrĺ ine, ki vsebuje polimerni material
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
AU2006335153B2 (en) 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
JP2010532383A (ja) * 2007-07-02 2010-10-07 エッセンシャリス，インク． カリウムａｔｐチャネル開口薬の塩およびその使用
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20110207718A1 (en) 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
WO2016077629A1 (en) 2014-11-14 2016-05-19 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
DE102015014581A1 (de) * 2015-11-12 2017-05-18 Nele Schmidt Prolamine enthaltende Gele, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS5630485A (en) * 1979-08-21 1981-03-27 Sansho Kk Heat insulation composition for heating and cooling
BE902605A (fr) * 1985-06-06 1985-09-30 Therabel Res S A N V Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4784857A (en) * 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3714074A1 (de) * 1987-04-28 1988-11-10 Hoechst Ag Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4857331A (en) * 1988-03-31 1989-08-15 Warner-Lambert Company Sugarless pectin delivery system
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5207932A (en) * 1989-07-20 1993-05-04 Chubb National Foam, Inc. Alcohol resistant aqueous film forming firefighting foam
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules
JPH04273818A (ja) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd 経皮投与製剤
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
JP3786684B2 (ja) * 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
JP2646170B2 (ja) * 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs

Also Published As

Publication number Publication date
WO1995023593A1 (en) 1995-09-08
HUT72981A (en) 1996-06-28
FI113337B (fi) 2004-04-15
HU9503054D0 (en) 1996-01-29
CN1111404C (zh) 2003-06-18
ES2180574T3 (es) 2003-02-16
JPH09501445A (ja) 1997-02-10
EP0700284B1 (en) 2002-08-28
DE69431247T2 (de) 2003-01-02
FI955215A0 (fi) 1995-11-01
FI955215A (fi) 1995-11-01
MX9501193A (es) 1998-07-31
DE69431247D1 (de) 2002-10-02
US5399359A (en) 1995-03-21
AU676556B2 (en) 1997-03-13
JP2005126444A (ja) 2005-05-19
CN1111507A (zh) 1995-11-15
CA2161103A1 (en) 1995-09-08
ATE222753T1 (de) 2002-09-15
PT700284E (pt) 2003-01-31
IL112637A0 (en) 1995-05-26
EP0700284A4 (en) 1996-11-06
CA2161103C (en) 1999-12-07
IL112637A (en) 1999-01-26
AU6588894A (en) 1995-09-18
EP0700284A1 (en) 1996-03-13
JP3699117B2 (ja) 2005-09-28

Similar Documents

Publication Publication Date Title
DK0700284T3 (da) Oxybutyninformuleringer med kontrolleret frigivelse
ES2191034T3 (es) Formulaciones de liberacion controlada para la liberacion de metoprolol durante 24 horas.
AU550992B2 (en) Sustained release diethylpropion comppositions
CA2164619A1 (en) Once-a-day metoprolol oral dosage form
DK0804166T3 (da) Formulering med kontrolleret frigivelse (Albuterol)
GEP20053474B (en) Glucocorticoid Receptor Modulators
DK0519820T3 (da) Matrixtablet, som muliggør længerevarende frigivelse af indapamid efter oral administration
IT8024603A0 (it) Formulazioni a cessione controllata a base di fenbendazolo intimamente disperso attraverso una matrice copolimera.
FI101855B1 (fi) Menetelmä asetatsolamidia jatkuvasti vapauttavan asetatsolamidivalmisteen valmistamiseksi